463 related articles for article (PubMed ID: 24517173)
1. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC
Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.
Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P; Vinks A; Sadhasivam S
Pharmacogenomics; 2017 Mar; 18(4):337-348. PubMed ID: 28244808
[TBL] [Abstract][Full Text] [Related]
3. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.
Fudin J; Atkinson TJ
Pain Med; 2014 May; 15(5):723-5. PubMed ID: 24636013
[No Abstract] [Full Text] [Related]
4. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
6. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing.
Linares OA; Fudin J; Daly AL; Boston RC
Clin J Pain; 2015 Dec; 31(12):1026-35. PubMed ID: 25621429
[TBL] [Abstract][Full Text] [Related]
7. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.
Andreassen TN; Eftedal I; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
Eur J Clin Pharmacol; 2012 Jan; 68(1):55-64. PubMed ID: 21735164
[TBL] [Abstract][Full Text] [Related]
8. Oxycodone findings and CYP2D6 function in postmortem cases.
Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 phenotype-specific codeine population pharmacokinetics.
Linares OA; Fudin J; Schiesser WE; Daly Linares AL; Boston RC
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):4-15. PubMed ID: 25562725
[TBL] [Abstract][Full Text] [Related]
10. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
Heiskanen T; Olkkola KT; Kalso E
Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
[TBL] [Abstract][Full Text] [Related]
11. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
12. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
[TBL] [Abstract][Full Text] [Related]
13. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
14. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
[TBL] [Abstract][Full Text] [Related]
15. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center.
Ramsey LB; Prows CA; Chidambaran V; Sadhasivam S; Quinn CT; Teusink-Cross A; Tang Girdwood S; Dawson DB; Vinks AA; Glauser TA
Am J Health Syst Pharm; 2023 Jun; 80(13):852-859. PubMed ID: 36715063
[TBL] [Abstract][Full Text] [Related]
16. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
17. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Ballester P; Muriel J; Peiró AM
Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
[TBL] [Abstract][Full Text] [Related]
19. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
Mas S; Gassó P; Torra M; Bioque M; Lobo A; González-Pinto A; Olmeda MS; Corripio I; Vieta E; Castro-Fornieles J; Rodriguez-Jimenez R; Bobes J; Usall J; Llerena A; Saiz-Ruiz J; Bernardo M; Lafuente A; PEPs Group
Eur Neuropsychopharmacol; 2017 Jul; 27(7):647-656. PubMed ID: 28389049
[TBL] [Abstract][Full Text] [Related]
20. Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: a randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model.
Litkowski LJ; Christensen SE; Adamson DN; Van Dyke T; Han SH; Newman KB
Clin Ther; 2005 Apr; 27(4):418-29. PubMed ID: 15922815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
